![Catherine E. Lucasey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Catherine E. Lucasey
Fondateur chez
TVAX BIOM
Profil
Catherine E.
Lucasey is the founder.
She founded TVAX Biomedical, Inc. in 2011, where she holds the title of Director, VP-Communications & Marketing.
She also founded TVAX Biomedical I LLC in 2004, where she holds the title of Director-Communications & Marketing.
In 1998, she founded Navigacom SAS and serves as the Chief Executive Officer.
Ms. Lucasey's former job was at the University of Kansas, where she worked as the Manager-Endocrine Division from 1990 to 2011.
Ms. Lucasey's education includes undergraduate and graduate degrees from Webster University.
Postes actifs de Catherine E. Lucasey
| Sociétés | Poste | Début |
|---|---|---|
| TVAX BIOM | Fondateur | 14/07/2011 |
TVAX Biomedical I LLC
 TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004. | Fondateur | 01/11/2004 |
NAVIGACOM
 NAVIGACOM Information Technology ServicesTechnology Services Operates as an IT strategy consulting firm | Directeur Général | 10/09/1998 |
Anciens postes connus de Catherine E. Lucasey
| Sociétés | Poste | Fin |
|---|---|---|
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/08/2011 |
Formation de Catherine E. Lucasey
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
92
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
TVAX Biomedical, Inc.
 TVAX Biomedical, Inc. BiotechnologyHealth Technology Manufactures and sells healthcare products | Health Technology |
University of Kansas
University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Webster University
 Webster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TVAX Biomedical I LLC
TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004. | |
NAVIGACOM
NAVIGACOM Information Technology ServicesTechnology Services Operates as an IT strategy consulting firm | Technology Services |
